Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
16.38
+1.51 (10.15%)
At close: Aug 4, 2026, 4:00 PM EDT
15.81
-0.57 (-3.48%)
After-hours: Aug 4, 2026, 7:34 PM EDT
Crescent Biopharma Revenue
In the year 2025, Crescent Biopharma had annual revenue of $10.84M.
Revenue (ttm)
$10.84M
Revenue Growth
n/a
P/S Ratio
59.00
Revenue / Employee
$216,055
Employees
55
Market Cap
701.08M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.84M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 10.00K | -65.00K | -86.67% |
| Dec 31, 2022 | 75.00K | -1.08M | -93.53% |
| Dec 31, 2021 | 1.16M | -9.00M | -88.59% |
| Dec 31, 2020 | 10.16M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 18.50K | -20.05M | -99.91% |
| Dec 31, 2015 | 20.07M | 5.04M | 33.56% |
| Dec 31, 2014 | 15.03M | 11.03M | 276.37% |
| Dec 31, 2013 | 3.99M | -11.26M | -73.83% |
| Dec 31, 2012 | 15.26M | 11.44M | 300.04% |
| Dec 31, 2011 | 3.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 400.05M |
| MiMedx Group | 355.17M |
| Gyre Therapeutics | 117.05M |
| REGENXBIO | 87.82M |
| Neurogene | 925.00K |
| Allogene Therapeutics | 22.00K |
CBIO News
- 1 day ago - Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewsWire
- 5 days ago - Crescent Biopharma reports Q2 EPS (74c), consensus (64c) - TheFly
- 5 days ago - Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 days ago - Crescent Biopharma Earnings release: Q2 2026 - Filings
- 5 days ago - Crescent Biopharma Quarterly report: Q2 2026 - Filings
- 19 days ago - Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 21 days ago - Crescent Biopharma 8.095M share Spot Secondary priced at $14.50 - TheFly
- 21 days ago - Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire